Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
Anacetrapib is a potent, reversible CETP inhibitor that is not only able to increase HDL-cholesterol, but also further decrease LDL-cholesterol when taken in combination with a statin. Safety and tolerability studies reported to date are promising. The results from Phase III trials investigating the efficacy of anacetrapib for the prevention of major coronary events in patients with atherosclerotic cardiovascular disorders are awaited with interest.
|
Authors | Amanda J Hooper, John R Burnett |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 21
Issue 1
Pg. 103-9
(Jan 2012)
ISSN: 1744-7658 [Electronic] England |
PMID | 22191425
(Publication Type: Journal Article)
|
Chemical References |
- Cholesterol Ester Transfer Proteins
- Cholesterol, HDL
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Oxazolidinones
- anacetrapib
|
Topics |
- Animals
- Atherosclerosis
(drug therapy, physiopathology)
- Cholesterol Ester Transfer Proteins
(antagonists & inhibitors)
- Cholesterol, HDL
(blood, drug effects)
- Cholesterol, LDL
(blood, drug effects)
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hypercholesterolemia
(complications, drug therapy)
- Hyperlipidemias
(complications, drug therapy)
- Oxazolidinones
(adverse effects, pharmacokinetics, pharmacology)
|